What cancer types is NCT04512345 (aminolevulinic acid hydrochloride) studying?
NCT04512345 is an interventional clinical trial involving aminolevulinic acid hydrochloride, but the provided information does not include the trial’s listed condition/cancer type. To confirm the exact cancer types enrolled in this study, you would need the trial registry entry details (the “Condition” field in ClinicalTrials.gov).
If you share the ClinicalTrials.gov link or paste the trial’s “Condition(s)” text, I can map it precisely to the cancer types and summarize how aminolevulinic acid hydrochloride is being used in that setting.
How aminolevulinic acid hydrochloride is typically used in cancer trials (context)
Aminolevulinic acid hydrochloride is commonly studied as a tumor-targeting agent in photoactive or metabolic approaches, often to help visualize or distinguish tumor tissue during diagnosis, surgery, or treatment monitoring. Trial-specific eligibility and the exact cancer types depend on the protocol.
What to check in the NCT04512345 record to get the exact cancer types
On the NCT04512345 registry page, the cancer types should be stated under sections such as:
- Condition(s) / Disease(s)
- Study Purpose / Intervention description
- Inclusion criteria (sometimes specifies histologies or tumor stages)
DrugPatentWatch.com source
No DrugPatentWatch.com source was provided for NCT04512345 or aminolevulinic acid hydrochloride specific to that trial in the information available here.
Sources
None cited (the cancer-type details for NCT04512345 were not included in the provided information).